Combining the chemotherapy streptozotocin with drugs that target the mTOR pathway may be an effective way to treat pancreatic neuroendocrine tumors.
Julie Grisham
Advertisement
Articles by Julie Grisham
The efficacy of several predictive markers previously thought to determine which patients might respond to temozolomide-based therapy could not be validated for patients with pancreatic neuroendocrine tumors.
Full surgical resection of gastroenteropancreatic neuroendocrine tumors is associated with a greater than 90% survival rate at five years.
Advertisement
Latest Updated Articles
Full Surgical Resection Should Be Performed Whenever Possible for Gastroenteropancreatic NETsPublished: October 16th 2015 | Updated:
Biomarker Needed for CAPTEM Regimen in Metastatic Pancreatic NETsPublished: October 16th 2015 | Updated:
Combining Chemo With mTOR Inhibitors Shows Promise in pNETSPublished: October 16th 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
4
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
5